Cory Anderson named EVP, GM of Greenbrook at Neuronetics (NASDAQ: STIM)
Rhea-AI Filing Summary
Neuronetics, Inc. announced that its board of directors has promoted Cory Anderson to Executive Vice President, General Manager of Greenbrook, effective July 1, 2026. He moves from his prior role as Senior Vice President, Chief Technology Officer and brings over 25 years of medical device leadership experience.
In connection with the promotion, Anderson’s annual base salary will increase to $425,000, and his target discretionary annual cash bonus will be set at 45% of his then-current base salary. He will remain eligible for annual equity grants under the company’s long‑term incentive program and continues under existing indemnification, restrictive covenant, and severance agreements.
Positive
- None.
Negative
- None.
8-K Event Classification
2 items: 5.02, 9.01
2 items
Item 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers
Governance
Key personnel changes including departures, elections, or appointments of directors and executive officers.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Key Figures
Base salary: $425,000 per year
Target bonus: 45% of base salary
Promotion effective date: July 1, 2026
+2 more
5 metrics
Base salary
$425,000 per year
Effective July 1, 2026 for EVP, GM of Greenbrook role
Target bonus
45% of base salary
Target discretionary annual cash bonus after promotion
Promotion effective date
July 1, 2026
Anderson Promotion Date to EVP, GM of Greenbrook
Anderson age
49 years
Age of newly promoted Executive Vice President
Experience
Over 25 years
Medical device industry and executive leadership experience
Key Terms
Executive Vice President, General Manager of Greenbrook, long-term incentive program, executive indemnification agreement, restrictive covenant and severance agreement
4 terms
Executive Vice President, General Manager of Greenbrook financial
"promoted Cory Anderson from the position of Senior Vice President, Chief Technology Officer to the position of Executive Vice President, General Manager of Greenbrook"
long-term incentive program financial
"Mr. Anderson will continue to be eligible to receive annual equity grants under the Company’s long-term incentive program"
A long-term incentive program is a company plan that pays executives or employees rewards—often stock, options, or cash—only if the business hits performance goals over several years. It matters to investors because these payouts align managers’ interests with shareholders, encouraging decisions that boost sustained growth and share value rather than short-term gains; think of it as a multi-year bonus tied to measurable company outcomes.
executive indemnification agreement financial
"Mr. Anderson had previously entered into the Company’s executive indemnification agreement"
restrictive covenant and severance agreement financial
"executive restrictive covenant and severance agreement, and restrictive covenant and invention assignment agreement"
FAQ
What executive leadership change did Neuronetics (STIM) disclose on June 16, 2026?
Neuronetics disclosed that its board promoted Cory Anderson to Executive Vice President, General Manager of Greenbrook, effective July 1, 2026. He previously served as Senior Vice President, Chief Technology Officer, following multiple prior R&D and clinical leadership roles within the company.
How is Cory Anderson’s compensation changing with his new role at Neuronetics (STIM)?
Effective July 1, 2026, Cory Anderson’s annual base salary will increase to $425,000. His target discretionary annual cash bonus will also rise, set at 45% of his then‑current base salary, while he remains eligible for annual equity grants under the long‑term incentive program.
What is Cory Anderson’s professional background before his promotion at Neuronetics (STIM)?
Cory Anderson has over 25 years of medical device experience, including roles at Sebacia, The Innovation Factory, Accuitive Medical Ventures, and Novoste Corporation. He has managed clinical trials, R&D pipelines, business development, marketing, and operations for multiple venture‑backed and ophthalmic portfolio companies.
What prior positions has Cory Anderson held within Neuronetics (STIM)?
Within Neuronetics, Anderson served as SVP R&D and Clinical, Chief Technology Officer since January 2025, SVP R&D and Clinical before that, VP R&D and Clinical, and VP Clinical Affairs and Medical Operations, Interim VP R&D, reflecting a steady progression through senior technical and clinical leadership roles.
Will Cory Anderson continue to receive equity-based incentives at Neuronetics (STIM)?
Yes. The filing notes that, as before his promotion, Cory Anderson will remain eligible to receive annual equity grants under Neuronetics’ long‑term incentive program. He is also party to the company’s standard executive indemnification, restrictive covenant, severance, and invention assignment agreements.
AI-generated analysis. How Rhea-AI works. Not financial advice.
